Novo Nordisk A/S (NVO) Shares Bought by Folketrygdfondet
Folketrygdfondet increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 13.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,914,192 shares of the company’s stock after buying an additional 803,608 shares during the period. Novo Nordisk A/S makes up about 11.6% of Folketrygdfondet’s investment portfolio, making the stock its 2nd largest position. Folketrygdfondet owned 0.35% of Novo Nordisk A/S worth $296,550,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of NVO. Proficio Capital Partners LLC increased its stake in Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after buying an additional 1,918 shares during the last quarter. AlphaMark Advisors LLC increased its stake in Novo Nordisk A/S by 1.1% in the second quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after buying an additional 30 shares during the last quarter. Parallel Advisors LLC increased its stake in Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after buying an additional 1,553 shares during the last quarter. Finally, Advisory Services Network LLC bought a new stake in Novo Nordisk A/S during the first quarter worth $127,000. Institutional investors and hedge funds own 6.01% of the company’s stock.
Shares of Novo Nordisk A/S (NYSE:NVO) traded down 0.80% during mid-day trading on Friday, reaching $47.24. The company’s stock had a trading volume of 2,410,377 shares. The firm has a market cap of $117.16 billion, a price-to-earnings ratio of 19.48 and a beta of 0.59. The company’s 50-day moving average is $44.12 and its 200 day moving average is $40.02. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $47.82.
The company also recently disclosed an annual dividend, which was paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st were given a $0.336 dividend. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date of this dividend was Friday, August 18th. This represents a dividend yield of 1.07%. Novo Nordisk A/S’s payout ratio is presently 36.44%.
A number of analysts recently weighed in on the company. BidaskClub upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, June 15th. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a report on Wednesday, June 21st. Four analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $53.00.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.